Company intelligence / Profile preview

BioImpact Capital

Boston, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

BioImpact Capital (operating with MPM under the brand MPM BioImpact) is a biotech-focused impact investment manager and company creator, affiliated with MPM Capital, managing multi‑billion‑dollar impact and venture funds that invest in and build private and public biotech companies developing transformative therapies across oncology, infectious disease, and other serious illnesses.

Industry: Investors

Partnerships

Manages Oncology Impact Fund and Oncology Impact Fund 2 in collaboration with UBS (OIF often referred to as UBS Oncology Impact Fund)Created and incubated Orna Therapeutics, which entered a multi‑program collaboration with a major global biopharmaceutical company (name not public in cited release) valued up to $3.75 billion for vaccines and cancer treatments

Beyond the preview

Go deeper on BioImpact Capital.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BioImpact Capital.

Explore the full profile